Minocycline delays but does not attenuate the course of experimental autoimmune encephalomyelitis in Streptococcus pneumoniae-infected mice

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 1, 2007, Pages 74-79

  Herrmann, Isabel ^a   Kellert, Markus ^a   Spreer, Annette ^a   Gerber, Joachim ^a   Eiffert, Helmut ^a   Prinz, Marco ^a   Nau, Roland ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Ceftriaxone; Lipoteichoic acids; Pneumolysin; Rifampicin

Indexed keywords

BACTERIAL PROTEIN; CEFTRIAXONE; LIPOTEICHOIC ACID; MINOCYCLINE; PNEUMOLYSIN; RIFAMPICIN; TEICHOIC ACID;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; ENZYME IMMUNOASSAY; FEMALE; IN VITRO STUDY; LATENT PERIOD; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MINOCYCLINE; PNEUMOCOCCAL INFECTIONS; RIFAMPIN; TEICHOIC ACIDS;

EID: 33845871432     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl446     Document Type: Article

References (44)

1. Andersen O, Lygner PE, Bergstrom T et al. Viral infections trigger multiple sclerosis relapses: A prospective seroepidemiological study. J Neurol 1993; 240: 417-2.
2. Buljevac D, Flach HZ, Hop WC et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125: 952-60.
3. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1: 1313-5.
4. Du C, Yao SY, Ljunggren-Rose A et al. Chlamydia pneumoniae infection of the central nervous system worsens experimental allergic encephalitis. J Exp Med 2002; 196: 1639-44.
5. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003; 4: 103-12.
6. Wu LX, Makela MJ, Roytta M et al. Effect of viral infection on experimental allergic encephalomyelitis in mice. J Neuroimmunol 1988; 18: 139-53.
7. Nogai A, Siffrin V, Bonhagen K et al. Lipopolysaccharide injection induces relapses of experimental autoimmune encephalomyelitis in nontransgenic mice via bystander activation of autoreactive CD4+ cells. J Immunol 2005; 175: 959-66.
8. Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000; 164: 5683-8.
9. Visser L, Jan de Heer H, Boven LA et al. Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J Immunol 2005; 174: 808-16.
10. Herrmann I, Kellert M, Schmidt H et al. Streptococcus pneumoniae infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Infect Immun 2006; 74: 4841-8.
11. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
12. Prinz M, Garbe F, Schmidt H et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006; 116: 456-64.
13. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
14. Ebert S, Gerber J, Bader S et al. Dose-dependent activation of microglial cells by Toll-like receptor agonists alone and in combination. J Neuroimmunol 2005; 159: 87-96.
15. Malley R, Henneke P, Morse SC et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-71.
16. Takeuchi O, Hoshino K, Kawai T et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11: 443-51.
17. Aasjord P, Nyland H. Antibodies to staphylococcal lipoteichoic acid in serum and in cerebrospinal fluid from patients with multiple sclerosis. Acta Pathol Microbiol Scand [C] 1981; 89: 333-8.
18. Spreer A, Lis A, Gerber J et al. Differences in clinical manifestation of Streptococcus pneumoniae infection are not correlated with in vitro production and release of the virulence factors pneumolysin and lipoteichoic and teichoic acids. J Clin Microbiol 2004; 42: 3342-5.
19. Stuertz K, Schmidt H, Eiffert H et al. Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to β-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin. Antimicrob Agents Chemother 1998; 42: 277-81.
20. Spreer A, Kerstan H, Böttcher T et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003; 47: 2649-54.
21. Nessler S, Dodel R, Bittner A et al. Effect of minocycline in experimental autoimmune encephalomyelitis. Ann Neurol 2002; 52: 689-90.
22. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-7.
23. Gerber J, Pohl K, Sander V et al. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother 2003; 47: 1313-7.
24. Aasjord P, Nyland H, Haaheim LR. Intrathecal synthesis of antibodies to staphylococcal antigens in multiple sclerosis patients. Acta Pathol Microbiol Immunol Scand [C] 1986; 94: 97-103.
25. Tuomanen E, Liu H, Hengstler B et al. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis 1985; 151: 859-68.
26. Hirst RA, Kadioglu A, O'Callaghan C et al. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol 2004; 138: 195-201.
27. Kengatharan KM, de Kimpe S, Robson C et al. Mechanism of gram-positive shock: Identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med 1998; 188: 305-15.
28. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15: 95-110.
29. Gerber J, Eiffert H, Fleischer H et al. Reduced release of DNA from Streptococcus pneumoniae after treatment with rifampin in comparison to spontaneous growth and ceftriaxone treatment. Eur J Clin Microbiol Infect Dis 2001; 20: 490-3.
30. van Langevelde P, van Dissel JT, Ravensbergen E et al. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: Quantitative measurements and biological reactivities. Antimicrob Agents Chemother 1998; 42: 3073-8.
31. Nau R, Wellmer A, Soto A et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 1999; 179: 1557-60.
32. Böttcher T, Gerber J, Wellmer A et al. Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis 2000; 181: 2095-8.
33. Böttcher T, Ren H, Goiny M et al. Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J Neurochem 2004; 91: 1450-60.
34. Azeh I, Gerber J, Wellmer A et al. Protein synthesis inhibiting clindamycin improves outcome in a mouse model of Staphylococcus aureus sepsis compared with the cell wall active ceftriaxone. Crit Care Med 2002; 30: 1560-4.
35. Schrijver IA, van Meurs M, Melief MJ et al. Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 2001; 124: 1544-54.
36. Korner H, Goodsall AL, Lemckert FA et al. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1995; 92: 11066-70.
37. Ruddle NH, Bergman CM, McGrath KM et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172: 1193-200.
38. Samoilova EB, Horton JL, Hilliard B et al. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998; 161: 6480-6.
39. Heumann D, Barras C, Severin A et al. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62: 2715-21.
40. Rothstein JD, Patel S, Regan MR et al. b-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433: 73-7.
41. Yong VW, Wells J, Giuliani F et al. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-51.
42. Yulug B, Kilic U, Kilic E et al. Rifampicin attenuates brain damage in focal ischemia. Brain Res 2004; 996: 76-80.
43. Brundula V, Rewcastle NB, Metz LM et al. Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-308.
44. Popovic N, Schubart A, Goetz BD et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-23.